Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID‐19?

Issam Nessaibia, Dafne Siciliano and Abdelkrim Tahraoui

International Journal of Health Planning and Management, 2020, vol. 35, issue 6, 1311-1313

Abstract: Chloroquine represents at least a basic prototype antimalarial drug, widely applied in several branches of medicine and also recently against a new zoonotic origin coronavirus. At present, there is little awareness of chloroquine's psychiatric side effects, which appear to be overlooked by the Scientific Committee, although they may manifest in a worryingly wide range of symptoms. This is likely to interfere with the course of specifically long‐term (high‐dose) COVID‐19 treatment in some aggravated forms (25% of coronavirus patients were still carrying the virus 6 days after taking hydroxychloroquine). Besides, symptoms of infection, adverse effects from the 600 mg hydroxychloroquine daily plus azithromycin, including insomnia, headaches, skin reactions, digestive upset with nausea, vomiting, and diarrhea, blurred vision, and local pain, may lead to increased anxiety and mental distress.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hpm.3057

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:ijhplm:v:35:y:2020:i:6:p:1311-1313

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0749-6753

Access Statistics for this article

International Journal of Health Planning and Management is currently edited by Calum Paton

More articles in International Journal of Health Planning and Management from Wiley Blackwell
Bibliographic data for series maintained by Wiley Content Delivery ().